Concepedia

Author

José María Viéitez

Hospital Universitario Central de Asturias

Also Known As

Fernando Rivera, J M Vieitez, J Vieitez, J. M Viéitez, J. M. Vieitez, J. M. Viéitez, J. Vieitez, J.M Vieitez, J.M. Vieitez, J.M. Viéitez

118

Publications

3.9K

Citations

23

H-Index

41

Concepts

All Affiliations

Hospital Universitario Central de AsturiasHospital General Universitario Gregorio MarañónInstituto Maimónides de Investigación Biomédica de CórdobaHospital Universitario 12 De OctubreHospital Universitario Reina Sofía
JM

About

José María Viéitez is an author at Hospital Universitario Central de Asturias specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

19

2K

2

Health Sciences

3

3

51

3

Biostatistics

2

2

86

4

Cell Biology

2

2

308

5

Public Health

1

1

30

José María Viéitez

×

31

Publications

3.5K

Citations

21

H-Index

YearCitations

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold,

The Lancet Oncology

2012

1.2K

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy,

Journal of Clinical Oncology

2001

1K

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

H. Cortés-Funes, Carlos Gegúndez Gómez, Rafael Rosell,

Annals of Oncology

2005

231

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Julieta Grasselli, Élena Elez, Ginevra Caratù,

Annals of Oncology

2017

189

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André,

Annals of Oncology

2013

101

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

Miguel J. Sotelo, Javier Sastre, M.L. Maestro,

Annals of Oncology

2014

77

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Angus Dalgleish, Justin Stebbing, Douglas JA Adamson,

British Journal of Cancer

2016

74

Uveitis as the initial clinical manifestation in patients with spondyloarthropathies.

Julia Fernández-Melón, Santiago Muñoz‐Fernández, Ventura Hidalgo,

PubMed

2004

63

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

Enrique Aranda, José María Viéitez, Auxiliadora Gómez‐España,

ESMO Open

2020

59

CISNE: An accurate description of dose-effect and synergism in combination therapies

Amador García‐Fuente, Fernando Vázquez, José María Viéitez,

Scientific Reports

2018

56

Page 1